Video

Dr. Chamie on Examining N-803 Plus BCG in BCG-Unresponsive NMIBC CIS

Karim Chamie, MD, discusses the design of the phase 2/3 QUILT-3.032 trial in patients with Bacillus Calmette-Guerín–unresponsive, non–muscle invasive bladder cancer carcinoma in situ.

Karim Chamie, MD, associate professor, Urology, UCLA Health, discusses the design of the phase 2/3 QUILT-3.032 trial (NCT0302282) in patients with Bacillus Calmette-Guerín (BCG)–unresponsive, non–muscle invasive bladder cancer carcinoma in situ.

BCG-unresponsive bladder cancer is not a disease that is common, and because of this, the FDA approves drugs that have achieved certain milestones, according to Chamie. For example, phase 3 trials where patients are randomized to placebo or the study drug are not necessary in the patient population. Instead, the FDA has allowed companies to develop single-arm studies in which every patient receives the investigational agent, Chamie adds.

As such, in the single-arm QUILT-3.032 study, every patient received N-803 plus BCG, Chamie concludes. At the 2021 AUA Annual Meeting, data from the interim analysis of cohort A of the trial, which was comprised of patients with BCG-unresponsive NMIBC carcinoma in situ (CIS). The primary end point of this cohort was incidence of complete response of CIS at any time, and it was met.

Related Videos
Antonio Cigliola, MD
Rohan Garje, MD
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Toni K. Choueiri, MD
Neil J. Shah, MBBS
Brian I. Rini, MD, FASCO
Laurence Albigès, MD, PhD
Antonio Cigliola, MD, medical oncologist, IRCCS San Raffaele Hospital
David Braun, MD, PhD